Assignee
SYROS PHARMACEUTICALS INC
US·25 granted patents·28 pending applications·73 citations·filing 2014–2025
Top patents by PatentIndex Score
53 records- 0194US10738067B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2020·Granted Aug 11, 2020·5 cites·30 claims
- 0293US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0392US12364664B2Lyophilized compositions comprising arsenicSYROS PHARMACEUTICALS INC·Filed 2023·Granted Jul 22, 2025·1 cites·18 claims
- 0492US10336760B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jul 2, 2019·11 cites·21 claims
- 0592US10059690B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·9 cites·19 claims
- 0690US9868994B2Methods of stratifying patients for treatment with retinoic acid receptor-α agonistsSYROS PHARMACEUTICALS INC·Filed 2017·Granted Jan 16, 2018·6 cites·22 claims
- 0786US10697025B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 30, 2020·3 cites·27 claims
- 0886US10308648B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jun 4, 2019·6 cites·20 claims
- 0985US10106526B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Oct 23, 2018·5 cites·19 claims
- 1084US10519135B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·3 cites·18 claims
- 1184US10240210B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2017·Granted Mar 26, 2019·2 cites·27 claims
- 1284US2024269076A1High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In PatientsSYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1383US12240869B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Mar 4, 2025·1 cites·27 claims
- 1482US11311542B2Inhibitors of cyclin dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Apr 26, 2022·3 cites·20 claims
- 1581US9845508B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2016·Granted Dec 19, 2017·4 cites·7 claims
- 1680US11053552B2Methods of stratifying patients for treatment with retinoic acid receptor-α agonistsSYROS PHARMACEUTICALS INC·Filed 2019·Granted Jul 6, 2021·1 cites·22 claims
- 1780US10167518B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2017·Granted Jan 1, 2019·3 cites·7 claims
- 1879US11124527B2Compounds for the modulation of Myc activitySYROS PHARMACEUTICALS INC·Filed 2016·Granted Sep 21, 2021·2 cites·30 claims
- 1979US10865206B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Dec 15, 2020·1 cites·25 claims
- 2074US2023042181A1Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2173US2026035393A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2272US2021107912A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2372US2024360165A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2471US2023144106A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2569US2021285059A1Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2667US11447831B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·0 cites·27 claims
- 2765US2021061803A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2865US2020010473A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2965US2019330218A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3063US11753418B2Compounds for the modulation of Myc activitySYROS PHARMACEUTICALS INC·Filed 2021·Granted Sep 12, 2023·0 cites·30 claims
- 3162US2021188833A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3262US2022305014A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3361US2023062491A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3461US2024102106A1Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3560US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3659US2021221820A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3758US11083728B2Compositions of cyclin dependent kinase 7 (CDK7) inhibitorSYROS PHARMACEUTICALS INC·Filed 2018·Granted Aug 10, 2021·0 cites·15 claims
- 3857US2021147431A1Pyrrolotriazine compounds and methods of inhibiting tam kinasesSYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3956US2024091183A1Treatment regimens with fixed doses of tamibaroteneSYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4055US10787444B2Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2016·Granted Sep 29, 2020·0 cites·25 claims
- 4153US2016264552A1Heteromaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4252US11040981B2Pyrrolotriazine compounds and methods of inhibiting TAM kinasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·0 cites·28 claims
- 4351US2019292167A1Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4449US2023285339A1Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitorsSYROS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4546US11918592B2Inhibitors of cyclin dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Mar 5, 2024·0 cites·26 claims
- 4646US11274103B2Compounds for the modulation of MYC activitySYROS PHARMACEUTICALS INC·Filed 2017·Granted Mar 15, 2022·0 cites·24 claims
- 4744US2016032387A1Methods and systems for evaluating genesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4844US2020071326A1Tam kinase inhibitorsSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4941US2020291018A1Tam kinase inhibitorsSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 5037US2022401489A1Compositions and methods for treating sickle cell diseaseSYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SYROS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →